ライフサイエンスコーパス: IL-33

1 IL-33 and its receptor ST2 are contributing factors to a

2 IL-33 autoamplified itself and ST2 protein expression in

3 IL-33 function in epithelial cells was examined by intra

4 IL-33 induced its own mRNA and ST2L mRNA expression in t

5 IL-33 is a cytokine with pleiotropic properties and effe

6 IL-33 is a known inducer of Th2 immune responses, but it

7 IL-33 is an IL-1 family cytokine that signals through it

8 IL-33 is an IL-1 family member protein that is a potent

9 IL-33 is known to promote type 2 immune responses throug

10 IL-33 potently liberates AA and elicits LTC(4), PGD(2),

11 IL-33 primarily induces the production of Th2-associated

12 IL-33 regulates T helper 2 (T(H)2) cell-mediated disease

13 IL-33 treatment is therefore an attractive adjunctive st

14 IL-33, a cytokine upregulated in inflammatory bowel dise

15 IL-33, an IL-1 family cytokine, is constitutively expres

16 IL-33- and IL1RL1-deficient mice showed defective iron r

17 IL-33-mediated 5-HT release activated enteric neurons, s

18 IL-33-stimulated mast cells produced a range of cytokine

19 IL-33-Treg signaling was also required for chronic colit

20 dy specifically inhibits signaling via IL-1, IL-33 and IL-36 in vitro.

21 Levels of IL-4, IL-13, IL-33, and IL-1beta were significantly higher in nasal a

22 roles for members of the IL-1 family-IL-18, IL-33, IL-36, IL-37, and IL-38-in inflammation and immun

23 gonist activity (IL-1alpha, IL-1beta, IL-18, IL-33, IL-36alpha, IL-36beta, and IL-36gamma), receptor

24 genous alarmins (eg, HMGB-1, ATP, IL-1alpha, IL-33) from recipient tissue.

25 nes of the IL-1 family (IL-1alpha, IL-1beta, IL-33, IL-36alpha, IL-36beta and IL-36gamma).

26 cytokines/chemokines (TNFa, IL-1beta, IL-22, IL-33, IL-17alpha, IL-2, MIP-2, and MCP-1), and neutroph

27 a had the opposite effect, decreasing IL-25, IL-33, and mucous metaplasia while increasing IL-17 expr

28 al alarmin cytokine responses such as IL-25, IL-33, and thymic stromal lymphopoietin, and increasing

29 onors were cultured in the presence of IL-3, IL-33, GM-CSF, thymic stromal lymphopoietin, or IL-25.

30 Interleukin-33 (IL-33) acts as an alarmin cytokine by alerting the syste

31 t-like subset that expresses interleukin-33 (IL-33) and thymic stromal lymphopoietin (TSLP).

32 We find that the cytokine interleukin-33 (IL-33) is expressed by adult hippocampal neurons in an e

33 For example, interleukin-33 (IL-33) plays an important role in refractory disorders s

34 Here, we report that interleukin-33 (IL-33) promotes the generation of inflammatory ILC2s (IL

35 t RAGE acts both upstream of interleukin-33 (IL-33) release and downstream of IL-33 release via RAGE-

36 ytes to systemically release interleukin-33 (IL-33), which synergized with intestinal tuft-cell-deriv

37 enic effects of the cytokine interleukin-33 (IL-33).

38 lease of a nuclear cytokine, interleukin-33 (IL-33).

39 orrelations identified nasal levels of IL-8, IL-33, and Betula verrucosa 1-specific IgG(4) (sIgG(4))

40 Nasal levels of IL-8, IL-33, sIgG(4) and sIgE could be predictive biomarkers f

41 Accordingly, IL-33 also suppressed erythropoietin-accelerated erythro

42 Accordingly, IL-33 knockout (IL-33(KO)) Tg+ mice were examined and co

43 In addition, IL-33 signaling in myeloid cells is crucial for airway i

44 her T(reg) cells also respond to the alarmin IL-33 to regulate specific aspects of the immune respons

45 ed that tumor-cell expression of the alarmin IL-33 was necessary and sufficient for eosinophil-mediat

46 ogenic production is promoted by the alarmin IL-33.

47 Although IL-33-mediated promotion of type 2 immune responses has

48 en together, our data indicate that although IL-33 modulates Th2 inflammatory responses and MUC5AC pr

49 mouse bone marrow-derived mast cells and an IL-33-dependent in vivo model of aspirin-exacerbated res

50 IL-33 or following helminth infection in an IL-33-dependent manner.

51 ive activation of macrophages may involve an IL-33-responsive third-party cell.

52 of proinflammatory cytokines KC, IP-10, and IL-33 in bronchoalveolar lavage (BAL) fluid.

53 Similar to IL-1alpha and IL-33, IL-37 is a dual-function cytokine in that IL-37 t

54 oid cells (ILC2s) and dependent on IL-25 and IL-33.

55 S and upregulate COX-2 upon IL-2, IL-25, and IL-33 plus thymic stromal lymphopoietin stimulation.

56 for IL-4 production after combined IL-3 and IL-33 treatment in mice.

57 In mast cells stimulated with IL-3 and IL-33, the Il9 CNS-25 enhancer is a potent regulator of

58 and IL-3 in basophils and by IL-3, IL-5, and IL-33 in eosinophils.

59 tatin compound (simvastatin) blocked ATP and IL-33 release by lowering the expression of VDAC-1 in th

60 d secretions of thromboxane A(2), CXCL7, and IL-33 by mouse platelets were all were blocked by a sele

61 5 and IL-13 production, BAL eosinophils, and IL-33 release compared to WT mice.

62 and IL-13 drove reciprocal ASC expansion and IL-33 expression.

63 Thymic stromal lymphopoietin and IL-33 signaling reciprocally enhanced each other's prote

64 uronal IL-33 are decreased in aged mice, and IL-33 gain of function mitigates age-related decreases i

65 with rTSLP or vehicle, TSLPR(-/-) mice, and IL-33 receptor-deficient (ST2(-/-) ) mice were challenge

66 is in mice increased IL-33 in BM plasma, and IL-33 was required for inflammation-dependent suppressio

67 through a CysLT(2)R-mediated, platelet- and IL-33-dependent pathway.

68 hylcyclodextrin also blocked ATP release and IL-33 secretion by decreasing the level of VDAC-1 expres

69 2 innate lymphoid cell (ILC2) responses and IL-33 release.

70 ms and raise the possibility of SERPINB1 and IL-33 as potential wound healing therapeutic targets.

71 bronchial epithelial cells expressed ST2 and IL-33 stimulation led to an increase in intracellular ca

72 In addition, TSLP and IL-33 synergistically promoted group 2 innate lymphoid c

73 tors thymic stromal lymphopoietin (TSLP) and IL-33 are consistently associated with adaptive Th2 immu

74 addition of three secreted factors, ANGPTL7, IL-33 and SERPINB2, significantly enhances the productio

75 Interventions included the anti-IL-33 receptor ST2, anti-TSLP, or both.

76 ere we evidence a striking proximity between IL-33(+) muscle mSCs and both large-fiber nerve bundles

77 In vitro IL-33trap binds IL-33 and inhibits IL-33 activity to a much stronger deg

78 mosomoides polygyrus, which binds and blocks IL-33.

79 For example, in asthma, both IL-33 and IL-1 are of major importance, as are IL-36 and

80 define muscle mSC subtypes that express both IL-33 and the receptor for the calcitonin-gene-related p

81 tivation of IL-3-primed human basophils, but IL-33 and other cytokines were dispensable for this effe

82 scent at homeostasis but can be activated by IL-33 to produce large amounts of type 2 cytokines and o

83 osure, ST2(+) T(reg) cells were activated by IL-33 to suppress IL-17-producing gammadelta T cells.

84 roids; however, IL-13, a cytokine induced by IL-33, markedly induces goblet cells and gene expression

85 peripheral blood human ILC2s is inducible by IL-33.

86 es of genes whose expression is inhibited by IL-33 in key cellular processes associated with atherosc

87 Finally, we show that AAMPhi polarized by IL-33-stimulated mast cells attenuated the encephalitoge

88 rthermore, we found that AAMPhi polarized by IL-33-stimulated mast cells could suppress proliferation

89 nate lymphoid cells (ILC2) are stimulated by IL-33 to increase IL-5 and IL-13 production and airway i

90 Tape stripping caused IL-33-driven upregulation of Il13 expression by skin MCs

91 2 macrophages, type 2 innate lymphoid cells, IL-33, IL-4, IL-13, and mucus) that directly hinders lar

92 gerhans cells, type 2 innate lymphoid cells, IL-33, TSLP) that have important roles in the developmen

93 Accordingly, ablation of the cognate IL-33 receptor St2 limits tumor growth, and reduces mast

94 erein we identify the dual function cytokine IL-33 as an orchestrator of the glioblastoma microenviro

95 The cytokine IL-33 and the chemokine CXCL13 were preferentially expre

96 The cytokine IL-33 is a well-established inducer of Th2 responses.

97 s express ST2, the receptor for the cytokine IL-33, and chemoattractant receptor-homologous molecule

98 wnstream of IL-33 release via RAGE-dependent IL-33-induced accumulation of type 2 innate lymphoid cel

99 ansmission and inflammation with depression, IL-33 with asthma) and found associations directly sugge

100 , which are in part dependent on ASC-derived IL-33.

101 d- versus intestinal epithelial cell-derived IL-33 during dextran sodium sulfate-induced colitis.

102 e lack of intestinal epithelial cell-derived IL-33 had no impact on disease severity or tissue recove

103 , whereas intestinal epithelial cell-derived IL-33 is dispensable.

104 Meanwhile, myeloid cell-derived IL-33 was required for airway inflammation, ST2(+) myelo

105 mast cells, we show that epithelial-derived IL-33 uniquely induced type 2 cytokines in mast cells, w

106 Thus, we show that myeloid-derived IL-33 functionally restrains colitic disease, whereas in

107 nist) before allergen challenge to determine IL-33 gene expression and release, extracellular ATP rel

108 mechanism by which RAGE mediates downstream IL-33-induced type 2 inflammatory responses is unknown.

109 This TIC-driven, IL-33-TGF-beta feedforward loop could potentially be exp

110 gate PD-1 function in pulmonary ILC2s during IL-33-induced airway inflammation.

111 of epithelial growth factor receptor (EGFR), IL-33 and receptor ST2 were investigated in bronchial bi

112 his study, we address the role of endogenous IL-33 and its autoamplification of the IL-33/ST2 pathway

113 These results suggest that endogenous IL-33 and its autoamplification of IL-33/ST2 pathway pla

114 Notably, exophilin-5 deletion enhanced IL-33 release and pathogenic Th2 responsiveness through

115 Alt-Ext or vehicle once or twice to evaluate IL-33 release and TSLP expression in the lung.

116 e CMV vector, we further show that exogenous IL-33 boosts vaccine-induced memory T cell responses, wh

117 We show that treatment with exogenous IL-33 results in a generalized downregulation of genes c

118 damage and inflammatory cytokine expression (IL-33 and IL-8) compared with other dominant nasal bacte

119 Finally, IL-33 was detectable during early B cell development in

120 mpared to controls at baseline and following IL-33 stimulation.

121 eveal a previously unrecognized function for IL-33, Tph1, and ICOS in promoting inflammatory ILC2 res

122 Among HSPCs, we found that the receptor for IL-33, ST2, is expressed preferentially and highly on er

123 nstitutive function of COX-1 is required for IL-33 to activate group IVa cytosolic phospholipase A(2)

124 cells (WAT-MSCs) can act as a reservoir for IL-33, especially after cell stress, but also provide ad

125 h a cell-intrinsic, ST2-independent role for IL-33 in early B cell development.

126 These results reveal a role for IL-33 in pathogenesis of anemia during inflammatory dise

127 However, roles for IL-33 in promoting CD8, Th1, and T regulatory cell respo

128 Importantly, the SAA1-FPR2-IL-33 axis was upregulated in nasal epithelial cells fro

129 amined and compared with IL-33 heterozygous (IL-33(HET)) Tg+ mice.

130 We identified IL-33 expression in the nucleus of progenitor B (pro-B)

131 In IL-33 knockout mice, the IL-33- and OVA-induced airway h

132 ted the immunomodulatory effects of CpG A in IL-33-induced airway hyperreactivity (AHR) and airway in

133 cient perinates, whereas it was abrogated in IL-33-treated mice.

134 ce enlargement, were somewhat exaggerated in IL-33(KO)/Tg+ mice compared with IL-33(HET)/Tg+ mice.

135 telet-adherent eosinophils; and increases in IL-33, IL-4, IL-5, and IL-13 levels in lung tissue.

136 17beta-E2 or PPT, but not DPN, increased IL-33 gene expression, release, and DUOX-1 production in

137 ammatory spondyloarthritis in mice increased IL-33 in BM plasma, and IL-33 was required for inflammat

138 Estrogen receptor -alpha signaling increased IL-33 release and ILC2-mediated airway inflammation.

139 Overall, this study shows that increased IL-33 levels drive a self-perpetuating amplification loo

140 ry, we predicted that compounds which induce IL-33 are likely to promote remyelination.

141 strogen signaling increases allergen-induced IL-33 release, ILC2 cytokine production, and airway infl

142 OVA also induced IL-33 and ST2 protein expression.

143 and exogenous TSLP increased Alt-Ext-induced IL-33 release into BALF, and ST2 deficiency decreased Al

144 caprost decreased Alternaria extract-induced IL-33 release by human bronchial epithelial cells.

145 During RSV infection, IL-33 is elevated and promotes immune cell activation, l

146 tivation and that a COX product(s) inhibited IL-33 release.

147 nting IL-33-ST2 interactions, and inhibiting IL-33 responses in vitro and in an in vivo mouse model o

148 In vitro IL-33trap binds IL-33 and inhibits IL-33 activity to a much stronger degree than soluble ST

149 Thus an intact IL-33/ST2 pathway is necessary for both Ag-dependent and

150 Furthermore, intestinal IL-33 expression is regulated by the microbiota as fecal

151 These findings provide insight into IL-33- and eosinophil-mediated tumor control, revealed w

152 RTH2-deficient ILC2s following transfer into IL-33-treated recipients, wild-type and CRTH2-deficient

153 h the mTOR pathway and altered intracellular IL-33 trafficking.

154 in a model of AERD in which MC activation is IL-33 driven.

155 Processed 25-kDa IL-33 protein was detected in bronchoalveolar lavage flu

156 Accordingly, IL-33 knockout (IL-33(KO)) Tg+ mice were examined and compared with IL-3

157 investigated here the roles of various known IL-33 activated signaling pathways in such inhibitory ac

158 IL1RL1 and its ligand IL-33 are known regulators of mature myeloid cells, but

159 We show that lung IL-33 drives inflammation and remodeling beyond the type

160 Mechanistically, IL-33 triggered calcium influx via a non-canonical signa

161 o study the signalling pathways that mediate IL-33 induced cytokine production, a culture system was

162 In ST2 knockout mice, IL-33 and OVA induced airway hyperresponsiveness and eos

163 As compared with IL-33(HET)/Tg+ mice, IL-33(KO)/Tg+ mice had complete absence of bronchoalveol

164 As compared with IL-33(HET)/Tg+ mice, IL-33(KO)/Tg+ mice had significantly reduced levels of T

165 In wild-type mice, IL-33 or OVA induced similar airway hyperresponsiveness

166 Loss of neuronal IL-33 or the microglial IL-33 receptor leads to impaired spine plasticity, reduc

167 r Alternaria challenge, suggesting that more IL-33 was available for ILC2 activation and that a COX p

168 inophilia is linked to both ILC2 and myeloid IL-33 signaling.

169 L-33 antagonist that outperforms the natural IL-33 decoy receptor and shows anti-inflammatory activit

170 ng physical association among muscle nerves, IL-33(+) mSCs, and Tregs has been reported, and invites

171 Memory precision and neuronal IL-33 are decreased in aged mice, and IL-33 gain of func

172 Loss of neuronal IL-33 or the microglial IL-33 receptor leads to impaired

173 We find that neuronal IL-33 instructs microglial engulfment of the extracellul

174 tion were both completely diminished, and no IL-33/ST2 autoamplification was observed.

175 Notably, IL-33 has a distinct N-terminal domain that mediates nuc

176 IL-33trap is a novel IL-33 antagonist that outperforms the natural IL-33 deco

177 Conversely, loss of nuclear IL-33 cripples recruitment, dramatically suppresses glio

178 r factor-kappaB in such inhibitory action of IL-33.

179 Given the known neuroreparative actions of IL-33 in experimental models of central nervous system (

180 Conversely, administration of IL-33 in healthy mice suppressed erythropoiesis, decreas

181 nscriptomic and immunophenotypic analyses of IL-33-expanded Tregs reveal an enhancement in graft-homi

182 opment and validation of a new antagonist of IL-33, termed IL-33trap, which combines the extracellula

183 ndogenous IL-33 and its autoamplification of IL-33/ST2 pathway play an important role in the inductio

184 preserved, although no autoamplification of IL-33/ST2 pathway was observed.

185 ) rescues antibiotic-associated depletion of IL-33.

186 ells and binding of the C-terminal domain of IL-33 to its receptor ST2 on targets such as CD4(+) Th2

187 rleukin-33 (IL-33) release and downstream of IL-33 release via RAGE-dependent IL-33-induced accumulat

188 for GATA transcription factors downstream of IL-33 signaling during the development of pre-RPMs that

189 at CRTH2-dependent effects lie downstream of IL-33, directly affecting the migration of ILC2s into in

190 al to this mechanism is the direct effect of IL-33-ST2 signaling on monocyte/macrophage differentiati

191 Thus, we reveal an important function of IL-33 and ILC2s in promoting tumor metastasis via their

192 addition, nuclear and secreted functions of IL-33 regulate chemokines that collectively recruit and

193 y inflammation, suggesting the importance of IL-33 signaling in these cells.

194 This study highlights the importance of IL-33-activated ILC2s in mediating RSV-triggered AHR and

195 fully functional, expanded independently of IL-33, and led to an almost complete Treg-dependent prot

196 anacardic acid resulted in the induction of IL-33.

197 hallenges, as well as increases in levels of IL-33, type 2 cytokines, and biochemical markers of mast

198 was associated with a greater recruitment of IL-33-expressing OPCs in mice which received anacardic a

199 diated primarily by extracellular release of IL-33 from stromal cells and binding of the C-terminal d

200 in and flurbiprofen augmented the release of IL-33 in bronchoalveolar lavage fluid after Alternaria c

201 nt mice were employed to examine the role of IL-33 and ST2 signaling in myeloid cells.

202 In this study, the role of IL-33 as a regulator of particulate vaccine adjuvant-ind

203 therapeutically important intrinsic role of IL-33 in T(reg) cell stability in cancer.

204 The role of IL-33/ILC2 axis in RSV-induced AHR inflammation and eosi

205 e aimed to elucidate the individual roles of IL-33-activated innate immune cells, including ILC2s and

206 he processing, mobilization and secretion of IL-33 by the airway epithelium.

207 protein expression blocked the secretion of IL-33.

208 II alveolar cells as a major local source of IL-33 during virus-driven exacerbation in human subjects

209 Therapeutic targeting of IL-33 or IL-5 reversed NK cell suppression and alleviate

210 ction, mucus obstruction is not dependent on IL-33.

211 duction by ILC2s in the presence of IL-25 or IL-33 (P = .031) and allergen-driven T(H)2 cytokines by

212 to RSV, poly(I:C), house dust mite (HDM) or IL-33 using RT-qPCR, Luminex and live cell imaging.

213 starting at the pro-B cell stage paralleling IL-33 expression.

214 Increased permeability, IL-33 levels, type 2 innate lymphoid cell activation, an

215 Inhibition of COX-1 prevented IL-33-induced phosphorylation of extracellular signal-re

216 ng cell surface detection of ST2, preventing IL-33-ST2 interactions, and inhibiting IL-33 responses i

217 ased tumor burden, increased VEGF-A, reduced IL-33, and enhanced vascularity.

218 d beta7-integrin blocking antibodies reduced IL-33-induced eosinophilic inflammation, mucus metaplasi

219 e models revealed that exophilin-5 regulates IL-33 production and the Th2 response.

220 ignals augments or diminishes, respectively, IL-33 production by muscle mSCs and later accumulation o

221 Data show that loss of CD11c-restricted IL-33 exacerbated tissue pathology, coinciding with incr

222 Myeloid-specific, IL-33-deficient or ST2-deficient mice were employed to e

223 Specifically, IL-33 blockade normalized persisting and exacerbating in

224 Specifically, IL-33-deficient T(reg) cells demonstrated attenuated sup

225 pression of tumorigenicity 2 receptor (ST2) (IL-33 receptor)-independent fashion.

226 l day 14, a similar increase in steady-state IL-33 levels resulted in increased mortality, enlarged a

227 and thus stimulates naive and co-stimulates IL-33-activated ILC2s.

228 how that TLR9 activation by CpG A suppresses IL-33-mediated AHR and airway inflammation through inhib

229 n in the murine lung in response to systemic IL-33 treatment was partially dependent on CRTH2.

230 We here demonstrate that IL-33 induced instantaneous peristaltic movement and fac

231 We demonstrate that IL-33 prevents C. difficile-associated mortality and epi

232 e marrow chimeric mice, we demonstrated that IL-33 deficiency resulted in an increased frequency of d

233 We find that IL-33 expression in a large subset of human glioma speci

234 We found that IL-33 could be sensed by EC cells, inducing release of 5

235 sistent with previous studies, we found that IL-33 polarized alternatively activated macrophages (AAM

236 We found that IL-33-activated ILC2s were crucial for the development o

237 We report that IL-33 does not directly induce goblet cell differentiati

238 Our findings reveal that IL-33 can promote immunosuppressive responses by polariz

239 erythroid progenitors in vitro, we show that IL-33 directly inhibited terminal maturation.

240 In this study, we show that IL-33 promotes the accumulation and recall kinetics of c

241 Coculture experiments showed that IL-33-stimulated mast cells polarized AAMPhi through pro

242 These data suggest that IL-33 attenuates the induction of cellular immune respon

243 The IL-33 receptor ST2 was not expressed within the developi

244 The IL-33-ST2 and the PGD(2)-CRTH2 pathways have both been i

245 The IL-33-ST2 pathway is an important initiator of type 2 im

246 The IL-33/ST2 signaling pathway is involved in both the onse

247 pared with IL-33(HET)/Tg+ mice, although the IL-33(KO)/Tg+ mice had significantly reduced levels of M

248 ad unusually high expression of PD-1 and the IL-33 receptor ST2.

249 ding of the complex interactions between the IL-33 and PGD(2)-CRTH2 pathways that regulate ILC2 popul

250 Thus, we show that H. polygyrus blocks the IL-33 pathway via both HpARI which blocks the cytokine,

251 ILC2s express the IL-33 receptor and are a major cell type thought to medi

252 we demonstrate a protective function for the IL-33-ST2 axis in bronchial epithelial repair, and impli

253 nges were abolished in mice deficient in the IL-33 receptor ST2.

254 ation and eosinophilia were evaluated in the IL-33-deficient and YetCre-13 Rosa-DTA mice.

255 In IL-33 knockout mice, the IL-33- and OVA-induced airway hyperresponsiveness and eo

256 ch combines the extracellular domains of the IL-33 receptor (ST2) and its coreceptor, IL-1 receptor a

257 , TGF-beta upregulates the expression of the IL-33 receptor gene Il1rl1 (encoding IL-1 receptor-like

258 protein and ERK1/2 kinases downstream of the IL-33 receptor, IL1RL1.

259 enous IL-33 and its autoamplification of the IL-33/ST2 pathway in Ag-dependent and Ag-independent ast

260 type 2 response and the contribution of the IL-33/ST2 signaling axis in allergic responses induced b

261 es of Treg populations activated through the IL-33/ST2 pathway, aiming to exploit their tolerogenic p

262 Thus, the IL-33-ST2 axis controls epithelial niche regeneration by

263 We intervened with the IL-33 cascade and sought to dissect its role, also in sy

264 In turn, these IL-33-responding FcepsilonRIalpha(+) macrophages send pa

265 Thus, IL-33 instructs the development of RPMs as a response to

266 Tregs that develop in response to IL-33 upregulate critical Treg-associated markers, yet w

267 tion of CRTH2-deficient ILC2s in response to IL-33 was due to altered ILC2 migration patterns.

268 rived eicosanoids synthesized in response to IL-33, a cytokine critical to innate type 2 immunity.

269 L-9, IL-13 and GM-CSF by ILC2 in response to IL-33, with inhibition of p38 having the greatest effect

270 tor ST2 mediate tissue repair in response to IL-33.

271 henotype in vitro and in vivo in response to IL-33.

272 but not IL-5, IL-9 or GM-CSF in response to IL-33.

273 d effectively blocks human PBMC responses to IL-33.

274 tokines thymic stromal lymphopoietin (TSLP), IL-33, and IL-25 are central regulators of type 2 immuni

275 Alternatively, biologics blocking TSLP, IL-33, IL-4 and IL-13, or IgE may help to achieve that.

276 erized by high receptor expression for TSLP, IL-33, and IL-25 further supports a role for these cytok

277 However, TSLP, IL-33, and IL-25 all regulate a broad spectrum of innate

278 This Review provides an overview of TSLP, IL-33, and IL-25 and the development of blocking antibod

279 st in developing biologics that target TSLP, IL-33, and IL-25.

280 Wild-type, IL-33 knockout, ST2 knockout mice were either intratrach

281 en regulated the differentiation of a unique IL-33-producing stromal cell population specific to the

282 esistant properties and further upregulating IL-33 expression.

283 In vivo, IL-33-induced intestinal goblet cell hyperplasia is depe

284 were both significantly attenuated, whereas IL-33-induced ST2L mRNA expression was preserved, althou

285 Whether IL-33 serves a pathogenic or protective role during infl

286 del to determine the mechanism through which IL-33 affects intestinal goblet cell differentiation.

287 ghts on the signaling pathways through which IL-33 inhibits the macrophage expression of key atherosc

288 as upregulated in ILC2s upon activation with IL-33 or following helminth infection in an IL-33-depend

289 type 2 response classically associated with IL-33 signaling.

290 C(-/-) mice, which were then challenged with IL-33 and assessed for AHR and lung inflammation.

291 c(-/-) mice, which were then challenged with IL-33 and assessed for airway hyperreactivity and lung i

292 O)) Tg+ mice were examined and compared with IL-33 heterozygous (IL-33(HET)) Tg+ mice.

293 As compared with IL-33(HET)/Tg+ mice, although the IL-33(KO)/Tg+ mice had

294 As compared with IL-33(HET)/Tg+ mice, IL-33(KO)/Tg+ mice had complete abs

295 As compared with IL-33(HET)/Tg+ mice, IL-33(KO)/Tg+ mice had significantl

296 ggerated in IL-33(KO)/Tg+ mice compared with IL-33(HET)/Tg+ mice.

297 CGRP in concert with IL-33 and neuromedin U (NMU) supported IL-5 but constrai

298 arrow-derived or peritoneal macrophages with IL-33 failed to promote arginase activity or expression

299 We also show that treatment with IL-33 increased serial replating ability and expression

300 2 immune responses and clinical trials with IL-33 inhibitors are underway in food allergy.